ArticleJournal of gastrointestinal cancer2025
Safety and Efficacy of Gastric Endoscopic Submucosal Dissection in a Non-academic Western Center.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEndoscopic submucosal dissection (ESD) is a minimally invasive technique used to treat gastrointestinal neoplasms. Lower incidence of gastric lesions results in fewer studies of gastric ESD in the West. We aimed to show the safety and efficacy of gastric ESD in a non-academic center as compared to the available studies, while adhering to established international guidelines.
methodsWe retrospectively analyzed gastric ESDs in our center between June 2015 and December 2024. Included were precancerous lesions, early gastric cancers (EGCs), neuroendocrine neoplasias, and subepithelial lesions. Patient demographics, lesion characteristics, procedural details, adverse events, and treatment outcomes were analyzed. Primary study outcomes included rates of complete R0 resection (horizontal and vertical margins free of GI neoplasia on histopathology), curative resection in EGCs (R0 with no lymphovascular invasion, as defined by JGES criteria), and adverse events. Secondary outcomes were recurrence and diagnostic discrepancies.
resultsOne hundred gastric ESDs were performed in 91 patients. Conversion to hybrid ESD/EMR was done in six cases. In one early case, ESD was aborted after intraprocedural perforation. R0 resection rates for all lesions were 91%, 100% for low-grade dysplasias, 100% for high-grade dysplasias, 80.9% for EGCs, and 100% for other indications. Curative resection was achieved in 78.7% of EGCs. Adverse events occurred in 11 (11%) cases. During the mean follow-up period of 21.8 ± 24.0 months, recurrence occurred in four of 73 patients with follow-up data (5.5%).
conclusionsOur results demonstrate ESD as a safe and effective option for gastric lesions in non-academic Western centers.
Indexed as
Identifiers
40877605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.